204 related articles for article (PubMed ID: 34282556)
1. Over-activation of EFTUD2 correlates with tumor propagation and poor survival outcomes in hepatocellular carcinoma.
Lv C; Li XJ; Hao LX; Zhang S; Song Z; Ji XD; Gong B
Clin Transl Oncol; 2022 Jan; 24(1):93-103. PubMed ID: 34282556
[TBL] [Abstract][Full Text] [Related]
2. EFTUD2 maintains the survival of tumor cells and promotes hepatocellular carcinoma progression via the activation of STAT3.
Tu M; He L; You Y; Li J; Yao N; Qu C; Huang W; Xu L; Luo R; Hong J
Cell Death Dis; 2020 Oct; 11(10):830. PubMed ID: 33024090
[TBL] [Abstract][Full Text] [Related]
3. A functional loop between YTH domain family protein YTHDF3 mediated m
Zhou R; Ni W; Qin C; Zhou Y; Li Y; Huo J; Bian L; Zhou A; Li J
J Exp Clin Cancer Res; 2022 Dec; 41(1):334. PubMed ID: 36471428
[TBL] [Abstract][Full Text] [Related]
4. Cell division cycle associated 8: A novel diagnostic and prognostic biomarker for hepatocellular carcinoma.
Cui XH; Peng QJ; Li RZ; Lyu XJ; Zhu CF; Qin XH
J Cell Mol Med; 2021 Dec; 25(24):11097-11112. PubMed ID: 34741389
[TBL] [Abstract][Full Text] [Related]
5. Potential targets and molecular mechanism of miR-331-3p in hepatocellular carcinoma identified by weighted gene coexpression network analysis.
Chi Q; Geng X; Xu K; Wang C; Zhao H
Biosci Rep; 2020 Jun; 40(6):. PubMed ID: 32537629
[TBL] [Abstract][Full Text] [Related]
6. A novel lncRNA MCM3AP-AS1 promotes the growth of hepatocellular carcinoma by targeting miR-194-5p/FOXA1 axis.
Wang Y; Yang L; Chen T; Liu X; Guo Y; Zhu Q; Tong X; Yang W; Xu Q; Huang D; Tu K
Mol Cancer; 2019 Feb; 18(1):28. PubMed ID: 30782188
[TBL] [Abstract][Full Text] [Related]
7. Regulator of Calcineurin 1 Gene Isoform 4, Down-regulated in Hepatocellular Carcinoma, Prevents Proliferation, Migration, and Invasive Activity of Cancer Cells and Metastasis of Orthotopic Tumors by Inhibiting Nuclear Translocation of NFAT1.
Jin H; Wang C; Jin G; Ruan H; Gu D; Wei L; Wang H; Wang N; Arunachalam E; Zhang Y; Deng X; Yang C; Xiong Y; Feng H; Yao M; Fang J; Gu J; Cong W; Qin W
Gastroenterology; 2017 Sep; 153(3):799-811.e33. PubMed ID: 28583823
[TBL] [Abstract][Full Text] [Related]
8. SWELL1 promotes cell growth and metastasis of hepatocellular carcinoma in vitro and in vivo.
Lu P; Ding Q; Li X; Ji X; Li L; Fan Y; Xia Y; Tian D; Liu M
EBioMedicine; 2019 Oct; 48():100-116. PubMed ID: 31597595
[TBL] [Abstract][Full Text] [Related]
9. Epidermal growth factor-containing fibulin-like extracellular matrix protein 1 (EFEMP1) suppressed the growth of hepatocellular carcinoma cells by promoting Semaphorin 3B(SEMA3B).
Hu J; Duan B; Jiang W; Fu S; Gao H; Lu L
Cancer Med; 2019 Jun; 8(6):3152-3166. PubMed ID: 30972979
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of Protein Phosphatase 1γ (PP1γ) Is Associated with Enhanced Cell Proliferation and Poor Prognosis in Hepatocellular Carcinoma.
Li C; Wu M; Zong G; Wan C; Liu Q; Zhou H; Hua L; Chen Y; Chen X; Lu C
Dig Dis Sci; 2017 Jan; 62(1):133-142. PubMed ID: 27921263
[TBL] [Abstract][Full Text] [Related]
11. Transmembrane protein 106C promotes the development of hepatocellular carcinoma.
Luo X; Han G; Lu R; Guan S; Wang Y; Ju L; Chen L; Shao J; Bian Z
J Cell Biochem; 2020 Nov; 121(11):4484-4495. PubMed ID: 32037603
[TBL] [Abstract][Full Text] [Related]
12. Downregulation of PRAME Suppresses Proliferation and Promotes Apoptosis in Hepatocellular Carcinoma Through the Activation of P53 Mediated Pathway.
Zhu H; Wang J; Yin J; Lu B; Yang Q; Wan Y; Jia C
Cell Physiol Biochem; 2018; 45(3):1121-1135. PubMed ID: 29439259
[TBL] [Abstract][Full Text] [Related]
13. Validation of ORAOV1 as a new treatment target in hepatocellular carcinoma.
Ha SY; Yeo SY; Lee KW; Kim SH
J Cancer Res Clin Oncol; 2021 Feb; 147(2):423-433. PubMed ID: 33161447
[TBL] [Abstract][Full Text] [Related]
14. TRIM59 promotes tumor growth in hepatocellular carcinoma and regulates the cell cycle by degradation of protein phosphatase 1B.
Ying H; Ji L; Xu Z; Fan X; Tong Y; Liu H; Zhao J; Cai X
Cancer Lett; 2020 Mar; 473():13-24. PubMed ID: 31875525
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of chaperonin containing TCP1, subunit 3 predicts poor prognosis in hepatocellular carcinoma.
Cui X; Hu ZP; Li Z; Gao PJ; Zhu JY
World J Gastroenterol; 2015 Jul; 21(28):8588-604. PubMed ID: 26229401
[TBL] [Abstract][Full Text] [Related]
16. Bromodomain-containing protein 7 (BRD7) as a potential tumor suppressor in hepatocellular carcinoma.
Chen CL; Wang Y; Pan QZ; Tang Y; Wang QJ; Pan K; Huang LX; He J; Zhao JJ; Jiang SS; Zhang XF; Zhang HX; Zhou ZQ; Weng de S; Xia JC
Oncotarget; 2016 Mar; 7(13):16248-61. PubMed ID: 26919247
[TBL] [Abstract][Full Text] [Related]
17. Upregulation of thyroid hormone receptor interactor 13 is associated with human hepatocellular carcinoma.
Ju L; Li X; Shao J; Lu R; Wang Y; Bian Z
Oncol Rep; 2018 Dec; 40(6):3794-3802. PubMed ID: 30542731
[TBL] [Abstract][Full Text] [Related]
18. RAB10 overexpression promotes tumor growth and indicates poor prognosis of hepatocellular carcinoma.
Wang W; Jia WD; Hu B; Pan YY
Oncotarget; 2017 Apr; 8(16):26434-26447. PubMed ID: 28460436
[TBL] [Abstract][Full Text] [Related]
19. LncRNA PCAT6 predicts poor prognosis in hepatocellular carcinoma and promotes proliferation through the regulation of cell cycle arrest and apoptosis.
Luo Y; Lin J; Zhang Y; Dai G; Li A; Liu X
Cell Biochem Funct; 2020 Oct; 38(7):895-904. PubMed ID: 32064636
[TBL] [Abstract][Full Text] [Related]
20. Downregulation of Nedd4L predicts poor prognosis, promotes tumor growth and inhibits MAPK/ERK signal pathway in hepatocellular carcinoma.
Zhao F; Gong X; Liu A; Lv X; Hu B; Zhang H
Biochem Biophys Res Commun; 2018 Jan; 495(1):1136-1143. PubMed ID: 29175326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
